Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - granisetron hydrochloride - oral tablet - 1mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

cubic pharmaceuticals ltd - granisetron hydrochloride - oral tablet - 1mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - granisetron hydrochloride - oral tablet - 1mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

crescent pharma ltd - granisetron hydrochloride - oral tablet - 1mg

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - topotecan hydrochloride, quantity: 4 mg - injection, powder for - excipient ingredients: sodium hydroxide; tartaric acid; hydrochloric acid; mannitol - for single agent therapy for the treatment of patients with: small cell lung carcinoma, after failure of first line chemotherapy. metastatic carcinoma of the ovary after failure of first-line or subsequent therapy. in combination with cisplatin for the treatment of patients with: histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.

Kenija - angleščina - Pharmacy and Poisons Board

ms pharma jordan king abdulla (ii) bin al-hussein industrial - granisetron hydrochloride ep - solution for injection - each ml contains: granisetron hydrochloride bp… - granisetron

Združene države Amerike - angleščina - NLM (National Library of Medicine)

northstar rx llc - granisetron hydrochloride (unii: 318f6l70j8) (granisetron - unii:wzg3j2mcol) - granisetron hydrochloride tablets are indicated for the prevention of: - nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. - nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. granisetron hydrochloride is contraindicated in patients with known hypersensitivity to the drug or any of its components.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - granisetron hydrochloride - concentrate for soln for inf - 1 mg/ml - serotonin (5ht3) antagonists

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 100 mg - injection, concentrated - excipient ingredients: hydrochloric acid; lactic acid; sodium hydroxide; water for injections; sorbitol - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - irinotecan hydrochloride trihydrate, quantity: 40 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid; sorbitol; lactic acid - irinotecan hydrochloride is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan hydrochloride is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.